Literature DB >> 29300898

Impact of human leukocyte antigen mismatch on lung transplant outcome.

Yoshito Yamada1, Tim Langner1, Ilhan Inci1, Christian Benden2, Macé Schuurmans2, Walter Weder1, Wolfgang Jungraithmayr1.   

Abstract

OBJECTIVES: Human leucocyte antigen (HLA) mismatch between donor and recipient has a differential impact on the outcome after transplant (Tx) among transplantable solid organs. Although the lung is considered a highly antigenic organ, the impact of HLA matching between the donor and the recipient has been shown to be heterogeneous on lung Tx outcome. To provide further evidence that HLA matching should be considered in the decision process prior to lung Tx, we evaluated the impact of donor/recipient HLA mismatch on the outcome after lung Tx at our institution.
METHODS: All patients who underwent lung Tx were analysed in this retrospective single-cohort study between 1994 and 2013 for HLA (-A, -B or -DR) matching between the donor and the recipient and their association with overall survival, the incidence of acute cellular rejection (ACR) and the development of chronic lung allograft dysfunction (CLAD).
RESULTS: In total, 371 (197 men) patients were included. Of these, 117 patients had no HLA match (0/6), 143 had a 1/6 match, 77 had 2/6 matches, 28 had 3/6 matches and 6 had 4/6 matches. One hundred and twenty-two (33%) patients experienced at least 1 episode of ACR and 172 (46%) patients developed CLAD. Univariate analysis showed a significant correlation between HLA mismatch and the development of CLAD, whereas multivariate analysis revealed that the number of HLA matches (hazard ratio 0.76; P = 0.002), antibodies to cytomegalovirus in either donors or recipients (hazard ratio 1.52; P = 0.036) and donor age (hazard ratio 1.03; P < 0.001) were independent risk factors for the development of CLAD. On the other hand, HLA matches did not correlate with the incidence of ACR and with the overall survival rate.
CONCLUSIONS: The number of HLA mismatches between donors and recipients after lung Tx did not correlate with ACR or with the overall survival. In contrast, HLA mismatch correlated with the development of CLAD and should therefore be considered a risk factor.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29300898     DOI: 10.1093/icvts/ivx412

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  5 in total

1.  Validation of a Simple, Rapid, and Cost-Effective Method for Acute Rejection Monitoring in Lung Transplant Recipients.

Authors:  Monica Sorbini; Gabriele Togliatto; Fiorenza Mioli; Erika Simonato; Matteo Marro; Margherita Cappuccio; Francesca Arruga; Cristiana Caorsi; Morteza Mansouri; Paola Magistroni; Alessandro Gambella; Luisa Delsedime; Mauro Giulio Papotti; Paolo Solidoro; Carlo Albera; Massimo Boffini; Mauro Rinaldi; Antonio Amoroso; Tiziana Vaisitti; Silvia Deaglio
Journal:  Transpl Int       Date:  2022-06-09       Impact factor: 3.842

2.  Usefulness of a preoperative inflammatory marker as a predictor of asymptomatic acute rejection after lung transplantation: a Japanese single-institution study.

Authors:  Takashi Kanou; Masato Minami; Naoki Wada; Soichiro Funaki; Naoko Ose; Eriko Fukui; Yasushi Shintani
Journal:  J Thorac Dis       Date:  2020-09       Impact factor: 2.895

3.  High-resolution human leukocyte antigen typing and early post-transplant outcomes: more than meets the eye.

Authors:  Annelore Sacreas; Stijn E Verleden
Journal:  Ann Transl Med       Date:  2020-02

Review 4.  Early Identification of Chronic Lung Allograft Dysfunction: The Need of Biomarkers.

Authors:  Adrien Tissot; Richard Danger; Johanna Claustre; Antoine Magnan; Sophie Brouard
Journal:  Front Immunol       Date:  2019-07-17       Impact factor: 7.561

5.  Generating low immunogenic pig pancreatic islet cell clusters for xenotransplantation.

Authors:  Marco Carvalho Oliveira; Emilio Valdivia; Murielle Verboom; Yuliia Yuzefovych; Hendrik Johannes Sake; Olena Pogozhykh; Heiner Niemann; Reinhard Schwinzer; Björn Petersen; Jochen Seissler; Rainer Blasczyk; Constança Figueiredo
Journal:  J Cell Mol Med       Date:  2020-03-25       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.